Skip to content

Search Results

No Matching Results

    Recently Viewed

      Listening...

      HomeLatest newsWhat you need to know about Johnson & Johnson’s 2022 first-quarter earnings
      what-you-need-to-know-about-johnson-and-johnsons-2022-first-quarter-earnings-lede.png

      What you need to know about Johnson & Johnson’s 2022 first-quarter earnings

      Check out this infographic breakdown of the company’s first-quarter 2022 performance, with key highlights from its Pharmaceutical, MedTech and Consumer Health businesses.

      Share Article
      share to
      q1-2022-quarterlyearnings-0422.png

      This morning, Johnson & Johnson shared its first-quarter performance.

      Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 144,000 employees across the globe working every day to help change the trajectory of health for humanity.

      “Even in the face of some macro-economic headwinds, Johnson & Johnson posted strong results for the quarter, continuing to deliver reliable growth and investing to advance our pipeline. We’re proud to announce a dividend increase for the 60th consecutive year, a key capital allocation priority. We remain well positioned to accelerate innovation as we evolve into a smarter era of healthcare, and work to successfully stand up the New Consumer Health Company,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson.

      For more details about the company’s 2022 first-quarter results, and to read a message from Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.


      An infographic showing key stats about Johnson & Johnson's first-quarter 2022 earnings

      Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.